alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
EXECUTIVE OFFICE OF THE PRESIDENT

OFFICE OF THE UNITED STATES TRADE REPRESENTATIVE

WASHINGTON, D.C. 20508

May 7, 2019

RE: Product Exclusion Request Number: USTR-2018-0025-2426

ASC Industries, Inc.:

I am pleased to notify you that the United States Trade Representative has determined to 

grant the above-referenced exclusion request submitted pursuant to the notice published at 83 FR 

32181 (‘July 11 notice’). The exclusion determination is set out in a formal notice which has 

been submitted to Office of the Federal Register for publication (‘the exclusion notice’). A prepublication version of the exclusion notice has been posted on the USTR website, at 

https://ustr.gov/sites/default/files/enforcement/301Investigations/Notice_of_Product_Exclusions

_05.09.19.pdf. 

The scope of the exclusion is governed by the formal HTSUS language in the annex to 

the product exclusion notice, and not by the product descriptions set out in any particular request 

for exclusion. An exclusion in response to your request has been granted by excluding from the 

additional tariffs the 10-digit HTSUS subheading under which your request was filed. 

In accordance with the July 11 notice, the exclusion applies as of the July 6, 2018 

effective date of the tariff action, and will extend for one year after the exclusion notice is 

published in the Federal Register. As stated in the exclusion notice, U.S. Customs and Border 

Protection will issue additional instructions on entry guidance and implementation.

Sincerely,

Joseph Barloon

General Counsel
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Next Generation Technology Holdings,
Inc. (the "Company") on Form 10-QSB for the period ending June 30, 2003 as filed
with the Securities and Exchange Commission on the date hereof (the "Report").
I, Carl Pahapill, Chief Executive Officer of the Company, certify, pursuant to
18 U.S.C. ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of
2002, that:

1) The Report fully complies with the requirements of section 13(a) or 15(d) of
the Securities Exchange Act of 1934; and

2) The information contained in the Report fairly presents, in all material
respects, the financial condition and result of operations of the Company.

September 12, 2003                             BY:  /S/ CARL PAHAPILL
                                               ------------------------------
                                               NAME: CARL PAHAPILL
                                               TITLE: CHIEF EXECUTIVE OFFICER



<PAGE>
United States Court of Appeals

For the First Circuit

No. 08-1569

PAUL SIMMONS; PEDRO VALENTIN; DENNIS BELDOTTI,

Plaintiffs, Appellees/Cross-Appellants,

v.

WILLIAM FRANCIS GALVIN,

in his capacity as Secretary of the Commonwealth of Massachusetts,

Defendant, Appellant/Cross-Appellee.

ERRATA SHEET

The opinion of this Court issued on July 31, 2009 is amended

as follows:

On page 41, line 15, "regulatory rather then" should be

replaced with "regulatory rather than"
**Exhibit
      32.1**




**CERTIFICATION
      OF THE PERIODIC REPORT**


**Pursuant
      to 18 U.S.C. Section 1350**


**As
      adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
      2002**




Pursuant
      to, and for purposes only of, 18 U.S.C. § 1350, the undersigned hereby certifies
      that (i) the Quarterly Report of Peoples Bancorp, Inc. on Form 10-Q for the
      quarter ended September 30, 2007, as filed with the Securities and Exchange
      Commission (the “Report”), fully complies with the requirements of Section 13(a)
      or 15(d) of the Securities Exchange Act of 1934, and (ii) information contained
      in the Report fairly presents, in all material respects, the financial condition
      and results of operations of Peoples Bancorp, Inc. and Subsidiary.






Date:
                November 13, 2007
            /s/
                Thomas G. StevensonThomas
                G. StevensonPresident/Chief
                Executive Officer&
                Chief Financial Officer
II 

117TH CONGRESS 

2D SESSION S. 4221 

To amend title 5, United States Code, to achieve parity between the costof-living adjustment with respect to an annuity under the Federal Employees Retirement System and an annuity under the Civil Service Retirement System, and for other purposes. 

IN THE SENATE OF THE UNITED STATES 

MAY 16, 2022 

Mr. PADILLA (for himself, Mrs. MURRAY, Mr. SANDERS, Mr. VAN HOLLEN, 

and Ms. WARREN) introduced the following bill; which was read twice and 

referred to the Committee on Homeland Security and Governmental Affairs 

A BILL 

To amend title 5, United States Code, to achieve parity 

between the cost-of-living adjustment with respect to an 

annuity under the Federal Employees Retirement System 

and an annuity under the Civil Service Retirement System, and for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Equal COLA Act’’. 


pbinns on DSKJLVW7X2PROD with $$_JOB
2 

•S 4221 IS

1 SEC. 2. INCREASE IN COLA FOR FERS ANNUITIES. 

2 (a) IN GENERAL.—Section 8462 of title 5, United 

3 States Code, is amended— 

4 (1) in subsection (a)— 

5 (A) in paragraph (1), by adding ‘‘and’’ at 

6 the end; 

7 (B) in paragraph (2), by striking ‘‘; and’’ 

8 and inserting a period; and 

9 (C) by striking paragraph (3); and 

10 (2) by amending subsection (b)(1) to read as 

11 follows: 

12 ‘‘(b)(1) Except as provided in subsection (c), effective 

13 December 1 of each year, each annuity payable from the 

14 Fund having a commencing date not later than such De15 cember 1 shall be increased by the percent change in the 

16 price index for the base quarter of such year over the price 

17 index for the base quarter of the preceding year in which 

18 an adjustment under this subsection was made, adjusted 

to the nearest 1 19 ⁄10 of 1 percent.’’. 

20 (b) EFFECTIVE DATE.—The amendments made by 

21 subsection (a) shall take effect on the date that is 90 days 

22 after the date of enactment of this Act. 

23 (c) APPLICATION.—The amendments made by sub24 section (a) shall apply to— 


pbinns on DSKJLVW7X2PROD with $$_JOB
3 

•S 4221 IS

1 (1) any cost-of-living adjustment under section 

2 8462 of title 5, United States Code, made after the 

3 effective date described in subsection (b); and 

4 (2) any annuity covered by section 8462 of title 

5 5, United States Code, commencing before, on, or 

6 after the effective date described in subsection (b). 

Æ 


pbinns on DSKJLVW7X2PROD with $$_JOB
EXECUTIVE OFFICE OF THE PRESIDENT

OFFICE OF THE UNITED STATES TRADE REPRESENTATIVE

WASHINGTON, D.C. 20508

September 17, 2019

RE: Product Exclusion Request Number USTR-2018-0025-3096

Hartland Controls, LLC: 

I am pleased to notify you that the United States Trade Representative has determined to 

grant the above-referenced exclusion request submitted pursuant to the notice published at 83 FR 

32181 (‘July 11 notice’). The exclusion determination is set out in a formal notice which has 

been submitted to Office of the Federal Register for publication (‘the exclusion notice’). A prepublication version of the exclusion notice has been posted on the USTR website, at 

https://ustr.gov/sites/default/files/enforcement/301Investigations/%2434_Billion_Exclusions_Gr

anted_September.pdf. 

The scope of the exclusion is governed by the formal HTSUS language in the annex to 

the product exclusion notice, and not by the product descriptions set out in any particular request 

for exclusion. An exclusion in response to your request has been granted by excluding from the 

additional tariffs products covered by a specially drafted description contained in the annex to 

the product exclusion notice. 

In accordance with the July 11 notice, the exclusion applies as of the July 6, 2018 

effective date of the tariff action, and will extend for one year after the exclusion notice is 

published in the Federal Register. As stated in the exclusion notice, U.S. Customs and Border 

Protection will issue additional instructions on entry guidance and implementation

Sincerely,

Joseph Barloon

General Counsel
Form of Amd. 2 to the Aleris Corp. 2010 Equity Incentive Plan Stock Opt. Agmt.



 Exhibit 10.12.2 

ALERIS CORPORATION 
 2010 EQUITY INCENTIVE PLAN 
 Form of 

AMENDMENT 2 TO THE 
 STOCK OPTION AWARD AGREEMENT 

                       
                     , 2011 
 TO:

 FROM: Aleris Corporation (formerly “Aleris Holding Company”) 

 

	Re:	Amendment 2 to Option Award Agreement 


On June 11, 2010 you were granted an option to purchase shares of common stock of Aleris Corporation (the “Company”) (the
“Option”) pursuant to an Award Agreement issued under the Company’s 2010 Equity Incentive Plan (the “Plan”) amended as of April 28, 2011 by Amendment 1 to the Award Agreement. 

In light of the Company becoming a public company, we have amended, restated and renamed the Plan as the 2011 Equity Incentive Plan and we are amending
the terms of your Award Agreement, effective immediately prior to the effectiveness of a 2011 initial public offering of the Company (the “IPO”), as follows: 
  

	1.	Section 1(e). Key Terms; Change of Control. The reference to Plan Section 11 in Section 1(e) is amended to Plan Section 12.


  

	2.	Section 2. Exercise. The last two sentences of Section 2 are deleted. 


 

	3.	Section 3. Early Termination of the Option. The references to Plan Sections 11 and 15(b) are amended to Plan Sections 12 and 17(b), respectively.


  

	4.	Section 4. Company Call Right. Section 4 is deleted. 

  

	5.	Section 6. Option Subject to Plan and Stockholders Agreement. Section 6 is amended to change the heading to Option Subject to Plan and
Sections 6 (a) and (b) are amended to read as follows: 

  

	 	(a)	Employee Acknowledgements. By entering into this Award Agreement, you agree and acknowledge that (i) the Option is subject in all respects to the Plan;
(ii) the Option is subject to Plan provisions under which, in certain circumstances, the Committee may terminate your Option and/or make adjustments to the kind and/or number of shares or property underlying the Option; and (iii) the
Committee has discretion to interpret and administer the Plan and this Award Agreement and its judgments made in accordance with the Plan are final. 


 
 8146190.3 








	 	(b)	Conflicts. In the event of a conflict between any term or provision contained herein and a term or provision of the amended and restated Plan, the term or
provision contained in the amended and restated Plan shall control. 

  

	6.	The acknowledgment and statement within the box in the Award Agreement is deleted. 


 

	7.	Effective Date of this Amendment. This Amendment is effective immediately prior to the effectiveness of the IPO. 


 

	8.	Continued Terms of Option. Except as otherwise amended in this Agreement, your Option remains subject in all respects to the terms and conditions of the Award
Agreement, Amendment 1 and the 2011 Equity Incentive Plan. A copy of the 2011 Equity Incentive Plan has been provided to you. 

  

	
	Sincerely,
	
	  
	Christopher R. Clegg
	Executive Vice President, General Counsel & Secretary


  
 2 


 8146190.3
EXECUTIVE OFFICE OF THE PRESIDENT

OFFICE OF THE UNITED STATES TRADE REPRESENTATIVE

WASHINGTON, D.C. 20508

July 3, 2019

RE: Product Exclusion Request Number USTR-2018-0025-3921

ECM Industries LLC:

The purpose of this letter is to inform you that the product exclusion request referenced 

above has been denied. As you are aware, USTR published a Federal Register notice (83 FR 

28710) on June 20, 2018, that announced the Trade Representative’s determination to impose an 

additional duty of 25 percent on certain products from China. On July 11, 2018, the Trade 

Representative published a Federal Register notice (83 FR 32181) which announced that a 

process had been established under which interested persons could request that products falling 

within a covered HTSUS subheading be excluded from the additional duties announced on June 

20.

Your request was reviewed in accordance with the factors and procedures set forth in 

Section B(1) of the July 11 notice. Based on that review, and after careful consideration, your 

request was denied because the request did not contain a sufficient product identification or was 

determined to be non-administrable.

Because USTR will grant exclusion requests on a product specific basis, you may still 

benefit from a product exclusion if a similar product is granted an exclusion. Products for which 

an exclusion has been granted will be periodically announced on the USTR website. Product 

exclusions will become legally effective once published in the Federal Register. 

Sincerely,

Joseph Barloon

General Counsel
117TH CONGRESS 

2D SESSION S. 4261 

AN ACT 

To suspend duties and other restrictions on the importation 

of infant formula to address the shortage of infant formula in the United States, and for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 
2 

†S 4261 ES

1 SECTION 1. SHORT TITLE. 

2 This Act may be cited as the ‘‘Fixing Our Regulatory 

3 Mayhem Upsetting Little Americans Act’’ or the ‘‘FOR4 MULA Act’’. 

5 SEC. 2. DUTY-FREE TREATMENT OF IMPORTS OF INFANT 

6 FORMULA. 

7 (a) IN GENERAL.—During the 90-day period begin8 ning on the date of the enactment of this Act, infant for9 mula shall enter the United States free of duty and free 

10 of quantitative limitation. 

11 (b) INFANT FORMULA DEFINED.—In this section, 

12 the term ‘‘infant formula’’ has the meaning given that 

13 term in section 201(z) of the Federal Food, Drug, and 

14 Cosmetic Act (21 U.S.C. 321(z)). 

Passed the Senate June 23, 2022. 

Attest: 

Secretary. 

117TH CONGRESS 

2D SESSION S. 4261 

AN ACT 

To suspend duties and other restrictions on the imfor other purposes. age of infant formula in the United States, and portation of infant formula to address the short-
EXECUTIVE OFFICE OF THE PRESIDENT

OFFICE OF THE UNITED STATES TRADE REPRESENTATIVE

WASHINGTON, D.C. 20508

November 19, 2018

RE: Product Exclusion Request Number: USTR-2018-0025-2134

Reelcraft Industries:

The purpose of this letter is to inform you that the product exclusion request referenced 

above has been denied. As you are aware, USTR published a Federal Register notice (83 FR 

28710) on June 20, 2018, that announced the Trade Representative’s determination to impose an 

additional duty of 25 percent on certain products from China. On July 11, 2018, the Trade 

Representative published a Federal Register notice (83 FR 32181) which announced that a 

process had been established under which interested persons could request that products falling 

within a covered HTSUS subheading be excluded from the additional duties announced on June 

20. 

Your request was reviewed in accordance with the factors and procedures set forth in 

Section B(1) of the July 11 notice. Based on that review, and after careful consideration, your 

request was denied because the request did not contain a sufficient product identification or was 

determined to be non-administrable.

Because USTR will grant exclusion requests on a product specific basis, you may still 

benefit from a product exclusion if a similar product is granted an exclusion. Products for which 

an exclusion has been granted will be periodically announced on the USTR website. Product 

exclusions will become legally effective once published in the Federal Register. 

Sincerely,

Stephen P. Vaughn
Exhibit 31.1
 CERTIFICATION PURSUANT TO
SECTION 302 (a) OF THE SARBANES-OXLEY ACT
      a)
    
    Designed such disclosure controls and procedures, or caused such disclosure controls and
procedures to be designed under our supervision, to ensure that material information relating
to the registrant, including, its consolidated subsidiaries, is made known to us by others
within those entities, particularly during the period in which this report is being prepared;
 b)
    
    Designed such internal control over financial reporting, or caused such internal control over
financial reporting to be designed under our supervision, to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles;
 c)
    
    Evaluated the effectiveness of the registrants disclosure controls and procedures and
presented in this report our conclusions about the effectiveness of the disclosure controls
and procedures, as of the end of the period covered by this report based on such evaluation;
and
 d)
    
    Disclosed in this report any change in the registrants internal control over financial
reporting that occurred during the registrants most recent fiscal quarter (the registrants
fourth fiscal quarter in the case of an annual report) that has materially affected, or is
reasonably likely to materially affect the registrants internal control over financial
reporting; and
  a)
    
    All significant deficiencies and material weaknesses in the design or operation of internal
control over financial reporting which are reasonably likely to adversely affect the
registrants ability to record, process, summarize and report financial information; and
 b)
    
    Any fraud, whether or not material, that involves management or other employees who have a
significant role in the registrants internal control over financial reporting.
  /s/ Jack H. BrownJack H. BrownChairman of the Board, President,
and Chief Executive Officer
(Principal Executive Officer)
<TABLE> <S> <C>

<ARTICLE>               5

<S>                                <C>
<PERIOD-TYPE>                            12-Mos
<FISCAL-YEAR-END>                   Dec-31-1999
<PERIOD-END>                        Dec-31-1999
<CASH>                                   84,458
<SECURITIES>                                  0
<RECEIVABLES>                         1,746,062
<ALLOWANCES>                                  0
<INVENTORY>                                   0
<CURRENT-ASSETS>                      1,971,330
<PP&E>                               49,821,238
<DEPRECIATION>                       26,856,930
<TOTAL-ASSETS>                       25,183,020
<CURRENT-LIABILITIES>                 2,665,795
<BONDS>                               1,300,000
<PREFERRED-MANDATORY>                         0
<PREFERRED>                                   0
<COMMON>                                 45,974
<OTHER-SE>                           15,855,821
<TOTAL-LIABILITY-AND-EQUITY>         25,183,020
<SALES>                              11,498,813
<TOTAL-REVENUES>                     11,944,239
<CGS>                                         0
<TOTAL-COSTS>                         3,236,123
<OTHER-EXPENSES>                         85,562
<LOSS-PROVISION>                              0
<INTEREST-EXPENSE>                      378,751
<INCOME-PRETAX>                       3,415,213
<INCOME-TAX>                          1,040,581
<INCOME-CONTINUING>                   2,374,632
<DISCONTINUED>                                0
<EXTRAORDINARY>                               0
<CHANGES>                                     0
<NET-INCOME>                          2,374,632
<EPS-BASIC>                                 .55
<EPS-DILUTED>                               .55


</TABLE>
EXHIBIT 32.1

SECTION 1350 CERTIFICATION OF CHIEF EXECUTIVE OFFICER

I, Friedhelm Blobel, Chief Executive
Officer of SciClone Pharmaceuticals, Inc. (the Registrant), do hereby certify in accordance with 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, based on my knowledge:



|(1) | the Annual Report on Form 10-K of the Registrant, to which this certification is attached as an exhibit (the Report), fully complies with the requirements
of section 13(a) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and
|--- | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



|(2) | the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.
|--- | -------------------------------------------------------------------------------------------------------------------------------------------------------



|                     |  |  |  |                                                
|-------------------- |  |  |  | -----------------------------------------------
|                     |  | 
|Date: March 31, 2011 |  |  |  | /S/    FRIEDHELM BLOBEL,
PH.D.                 
|                     |  |  |  | Friedhelm Blobel, Ph.D. Chief Executive Officer

A signed original of this written
statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been
provided to SciClone Pharmaceuticals, Inc. and will be retained by SciClone Pharmaceuticals, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.
Exhibit 32.2

Certification

Pursuant to 18 U.S.C. Section 1350

as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Annual Report of Apria
Healthcare Group Inc. (the Company) on Form 10-K for the year ended December 31, 2010, as filed with the Securities and Exchange Commission on February 25, 2011 (the Report), I, Chris A. Karkenny, Executive
Vice President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:



| | (i) | The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and
| | --- | -------------------------------------------------------------------------------------------------------------------------------------



| | (ii) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| | ---- | ----------------------------------------------------------------------------------------------------------------------------------------------------



|                                                    
|----------------------------------------------------
|Date: February 25, 2011                             
|                                                    
|/s/ CHRIS A. KARKENNY                               
|Chris A. Karkenny                                   
|Executive Vice President and Chief Financial Officer